Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions

Bosiers, Marc; Deloose, Koen; Callaert, Joren; Moreels, Nathalie; Keirse, Koen; Verbist, Jürgen; Peeters, Patrick

doi:10.1016/j.jvs.2011.03.272

Cited by 138 publications

(108 citation statements)

References 18 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…The 1-year primary patency rate was 46 % for thrupass and 84 % for bypass (p = 0.18). Bosiers et al [6] published the DURABILITY-200 trial, a single-arm, two-center study, with 100 patients having a mean SFA lesion length of 24 cm, treated with the Protégé EverFlex Stent (Covidien Inc., Plymouth, Minnesota). At 1 year, the primary patency rate was 64 %, and freedom from TLR was 68 %.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Sustained Benefit at 2 Years for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial

Lämmer

Zeller

Hausegger

et al. 2014

Cardiovasc Intervent Radiol

106

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…However, the durability of percutaneous transluminal balloon angioplasty (PTA) for long SFA lesions remains poor [3,4]. Primary stent placement in long SFA lesions has shown promising results in single-arm studies [5][6][7][8][9][10]. However, in bare-metal stents (BMS) the risk of in-stent restenosis and stent fracture grows with lesion length [11].…”

mentioning

confidence: 99%

Sustained Benefit at 2 Years for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial

Lämmer

Zeller

Hausegger

et al. 2014

Cardiovasc Intervent Radiol

106

View full text Add to dashboard Cite

show abstract

“…The reduced need for stenting has distinct advantages. Although stenting improves patency compared with PTA, 18-21 TLR rate has remained high on follow-up ranging from 19 to 37% 18,19,22,23 at 1 year and up to 49% at 2 years. 20 The main mechanism of reducing restenosis with stenting is the reduction of elastic recoil and negative remodeling with no impact on SMC proliferation.…”

Section: Review Articlementioning

confidence: 99%

An Overview of Optimal Endovascular Strategy in Treating the Femoropopliteal Artery: Mechanical, Biological, and Procedural Factors

Shammas¹

2013

Int J Angiol

View full text Add to dashboard Cite

ReviewPeripheral arterial disease is highly prevalent in the general population affecting 12 to 14% of people and leading to claudication or threatened limb ischemia. 1 Endovascular lower extremity arterial interventions have increased exponentially over the past decade. 2 The femoropopliteal (FP) segment represents 40% of vessels treated and its treatment continues to be a challenge to the endovascular specialist. Despite a high rate of acute procedural success, target lesion revascularization (TLR) and target vessel revascularization remain elevated. 3,4 We have previously proposed a triad of optimal peripheral vascular revascularization strategy (►Fig. 1) 5 with an emphasis on three key principles: (1) Mechanical, improve vessel compliance to allow dilatation of a stenotic segment at low balloon inflation pressure and reduce dissection and recoil. Low balloon inflation pressure would theoretically preserve vessel integrity by minimizing barotrauma and bailout stenting. (2) Biological, inhibit smooth muscle cell (SMC) proliferation to improve patency rates and reduce repeat revascularization. (3) Procedural, preserve the outflow vessels by minimizing distal embolization (DE) and reduce procedural time and radiation exposure to both operator and patient.In this overview, we examine these principles to determine whether current data support their validity. We recognize the lack of uniform performance criteria and reporting standards in clinical trials in peripheral arterial disease. This unfortunately makes comparisons across studies difficult. Mechanical FactorsThe concept of improving vessel compliance as a prerequisite to a more definitive treatment of the FP artery has gained more attention over the past few years. Measurement of vessel compliance in vivo is difficult to obtain. One surrogate endpoint is the minimum balloon pressure (MBP) needed to fully stretch the artery to a lumen diameter equal to a normal reference segment with the use of a noncompliant balloon sized 1:1 to the reference vessel. The balloon is typically inflated to two atmospheres then the inflation pressure is increased by increment of one atmosphere at a time until full balloon expansion is achieved. 6,7 According to Laplace's law, tension (T) in the vessel wall is equal to (pressure (P) gradient across the arterial wall * radius (R) of artery)/wall thickening (M), or (T¼ [P * R]/M). In order for MBP change to reflect on compliance, the segments under comparison need to have similar radius and lesion Keywords AbstractTreatment of the femoropopliteal (FP) artery remains a challenge to the endovascular specialist. Long-term patency is low with a high rate of target lesion revascularization. The true patency rate varies considerably between studies partly because there is a lack of uniform performance criteria and reporting standards in peripheral arterial interventions. Literature review supports three principles that emerge as important components of an optimal strategy in treating the FP artery: (1) improving vessel compliance and sub...

show abstract

“…As a result of guideline recommendations encouraging mainly an endovascular first-line approach 1,2 and the development of new-generation nitinol stents, stenting of femoropopliteal lesions has become mainstream in recent years. However, midterm and long-term primary patency rates are suboptimal, with 1-year primary patency of 65% to 81% [3][4][5][6] for slotted-tube nitinol stents, 83% to 86% for interwoven-wire nitinol stents, 7,8 and 83% 9 for drug-eluting stents. Five-year primary patency after endovascular therapy is reported to be 50% for TransAtlantic InterSociety Consensus A to C lesions and 34% for D lesions.…”

mentioning

confidence: 99%

Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis

et al. 2015

View full text Add to dashboard Cite

Background-Drug-coated balloon angioplasty (DCBA) was shown to be superior to standard balloon angioplasty (POBA) in terms of restenosis prevention for de novo superficial femoral artery disease. For in-stent restenosis, the benefit of DCBA over POBA remains uncertain. Methods and Results-One hundred nineteen patients with superficial femoral artery in-stent restenosis and chronic limb ischemia were recruited over 34 months at 5 German clinical sites and prospectively randomized to either DCBA (n=62) or POBA (n=57

show abstract

Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions

Abstract: The results of our Durability-200 study show an acceptable primary patency rate after 1 year was obtained in this patient cohort with TASC C and D femoropopliteal lesions.

Cited by 138 publications

References 18 publications

Sustained Benefit at 2 Years for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial

Sustained Benefit at 2 Years for Covered Stents Versus Bare-Metal Stents in Long SFA Lesions: The VIASTAR Trial

An Overview of Optimal Endovascular Strategy in Treating the Femoropopliteal Artery: Mechanical, Biological, and Procedural Factors

Drug-Coated Balloon Versus Standard Balloon for Superficial Femoral Artery In-Stent Restenosis

Contact Info

Product

Resources

About